Am. Alak et Pp. Lizak, QUALITY ASSURANCE PROCEDURE FOR MONITORING TACROLIMUS (FK506) CONCENTRATIONS IN WHOLE-BLOOD BY IMX ASSAY, Therapeutic drug monitoring, 18(3), 1996, pp. 267-272
A Quality Assurance Program for the IMx assay for FK506 in whole blood
samples was established to monitor the performance of the assay in cl
inical sites enrolled by Fujisawa USA, Inc. Forty investigative sites
participating in the program were required to perform assays to establ
ish intraassay variability, interassay variability, and performance on
blinded samples. Only two of the sites were required to repeat part o
f the program. The intraassay and interassay results at the sites were
in good agreement with the target values obtained at Fujisawa Researc
h Laboratory. Most of the coefficients of variation (CV) were within /-15%, well within the acceptance range of +/-30%. Only a few values w
ere outside the acceptance window. For the blinded samples, the CVs we
re variable and depended on the concentration of FK506 in the sample.
At lower blood FK506 concentrations (5-10 ng/ml), the mean CVs were of
ten outside the acceptance window, and many individual values were not
acceptable. At concentrations of 15-50 ng/ml, the CVs were generally
acceptable. Thus individual sites can quickly learn to perform the FK5
06 IMx assay and achieve good within- and between-day results. The ass
ay of lower blood concentrations of FK506 may show higher variability.
Patients are usually monitored for clinical signs of rejection and to
xicity in addition to blood FK506 concentrations.